Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Colonic Neoplasms 226Colorectal Neoplasms 203Rectal Neoplasms 194Pancreatic Neoplasms 158Carcinoma, Hepatocellular 109Stomach Neoplasms 94Esophageal Neoplasms 81Liver Neoplasms 72Breast Neoplasms 68Lung Neoplasms 53Neoplasms 48Carcinoma, Non-Small-Cell Lung 47Neoplasm Metastasis 46Ovarian Neoplasms 44Sarcoma 43Bile Duct Neoplasms 38Gallbladder Neoplasms 37Melanoma 33Anus Neoplasms 31Prostatic Neoplasms 30Adenocarcinoma Of Esophagus 29Lymphoma, Non-Hodgkin 28Carcinoma, Renal Cell 28Uterine Cervical Neoplasms 27Osteosarcoma 27Gastrointestinal Stromal Tumors 27Gastrointestinal Neoplasms 27Neuroectodermal Tumors, Primitive, Peripheral 25Neuroblastoma 25Wilms Tumor 24

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Xeroderma Pigmentosum × Gastrointestinal × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡